Preparation of 5-heteroaryl thiazoles and their use as phosphoinositide 3-kinase (PI3K) inhibitors

Chloe Atkinson2017-11-07T15:58:41+00:00

1. Preparation of 5-heteroaryl thiazoles and their use as phosphoinositide 3-kinase (PI3K) inhibitors Bengtsson, Malena; Larsson, Joakim; Nikitidis, Grigorios; Storm, Peter; Bailey, John, Peter; Griffen, Edward, Jolyon; Arnould, Jean-Claude; Bird, Thomas, Geoffrey, Colerick WO 2006051270 A1.

Preparation of 5-heteroaryl thiazoles and their use as phosphoinositide 3-kinase (PI3K) inhibitorsChloe Atkinson2017-11-07T15:58:41+00:00

Preparation of thiazole derivatives as antitumor agents

Chloe Atkinson2017-11-07T15:58:12+00:00

2. Preparation of thiazole derivatives as antitumor agents Arnould, Jean-Claude; Foote, Kevin Michael; Griffen, Edward Jolyon WO 2007129044 A1.

Preparation of thiazole derivatives as antitumor agentsChloe Atkinson2017-11-07T15:58:12+00:00

Indole derivatives, processes for preparing them, pharmaceutical compositions containing them, and their use as inhibitors of PI3K and /or mTOR kinase

Chloe Atkinson2017-11-07T15:57:48+00:00

3. Indole derivatives, processes for preparing them, pharmaceutical compositions containing them, and their use as inhibitors of PI3K and /or mTOR kinase Foote, Kevin Michael; Griffen, Edward Jolyon WO 2007135398 A1.

Indole derivatives, processes for preparing them, pharmaceutical compositions containing them, and their use as inhibitors of PI3K and /or mTOR kinaseChloe Atkinson2017-11-07T15:57:48+00:00

Pyrimidine derivatives as antiproliferative agents and their preparation, pharmaceutical compositions and use in the treatment of diseases

Chloe Atkinson2017-11-07T15:57:16+00:00

4. Pyrimidine derivatives as antiproliferative agents and their preparation, pharmaceutical compositions and use in the treatment of diseases Butterworth, Sam; Griffen, Edward Jolyon; Hill, George Beresford; Pass, Martin WO 2008032027 A1.

Pyrimidine derivatives as antiproliferative agents and their preparation, pharmaceutical compositions and use in the treatment of diseasesChloe Atkinson2017-11-07T15:57:16+00:00

Preparation of pyrimidine derivatives having inhibitory activity against PI3K enzymes

Chloe Atkinson2017-11-07T15:56:53+00:00

5. Preparation of pyrimidine derivatives having inhibitory activity against PI3K enzymes Butterworth, Sam; Griffen, Edward Jolyon; Pass, Martin WO 2008032041 A1.

Preparation of pyrimidine derivatives having inhibitory activity against PI3K enzymesChloe Atkinson2017-11-07T15:56:53+00:00

Preparation of pyrimidine derivatives having inhibitory activity against PI3K enzymes

Chloe Atkinson2017-11-07T15:56:33+00:00

6. Preparation of pyrimidine derivatives having inhibitory activity against PI3K enzymes Butterworth, Sam; Griffen, Edward Jolyon; Pass, Martin WO 2008032064 A1.

Preparation of pyrimidine derivatives having inhibitory activity against PI3K enzymesChloe Atkinson2017-11-07T15:56:33+00:00

Preparation of pyrimidine derivatives for treating proliferative disorders sensitive to inhibition of PI3K and/or mTOR kinase.

Chloe Atkinson2017-11-07T15:56:10+00:00

7. Preparation of pyrimidine derivatives for treating proliferative disorders sensitive to inhibition of PI3K and/or mTOR kinase. Butterworth, Sam; Griffen, Edward Jolyon; Pass, Martin WO 2008032077 A1.

Preparation of pyrimidine derivatives for treating proliferative disorders sensitive to inhibition of PI3K and/or mTOR kinase.Chloe Atkinson2017-11-07T15:56:10+00:00

Preparation of 6-benzimidazolyl-2-morpholino-4-(azetidine, pyrrolidine, piperidine, or azepine) pyrimidine derivatives as PI3K and mTOR kinase inhibitors for the treatment of proliferative disorders

Chloe Atkinson2017-11-07T15:55:46+00:00

8. Preparation of 6-benzimidazolyl-2-morpholino-4-(azetidine, pyrrolidine, piperidine, or azepine) pyrimidine derivatives as PI3K and mTOR kinase inhibitors for the treatment of proliferative disorders Butterworth, Sam; Griffen, Edward Jolyon; Hill, George Beresford; Pass, Martin WO 2008032036 A1.

Preparation of 6-benzimidazolyl-2-morpholino-4-(azetidine, pyrrolidine, piperidine, or azepine) pyrimidine derivatives as PI3K and mTOR kinase inhibitors for the treatment of proliferative disordersChloe Atkinson2017-11-07T15:55:46+00:00

Preparation of 4-benzimidazolyl-6-morpholino-2-piperidinyl-4-pyrimidine derivatives as PI3K and mTOR kinase inhibitors for the treatment of proliferative disorder

Chloe Atkinson2017-11-07T15:55:14+00:00

9. Preparation of 4-benzimidazolyl-6-morpholino-2-piperidinyl-4-pyrimidine derivatives as PI3K and mTOR kinase inhibitors for the treatment of proliferative disorder Butterworth, Sam; Griffen, Edward Jolyon; Pass, Martin WO 2008032091 A1.

Preparation of 4-benzimidazolyl-6-morpholino-2-piperidinyl-4-pyrimidine derivatives as PI3K and mTOR kinase inhibitors for the treatment of proliferative disorderChloe Atkinson2017-11-07T15:55:14+00:00

Preparation of 4-benzimidazolyl-6-morpholino-2-piperazinyl-pyrimidine derivatives as PI3K and mTOR kinase inhibitors for the treatment of proliferative disorder

Chloe Atkinson2017-11-07T15:54:42+00:00

10. Preparation of 4-benzimidazolyl-6-morpholino-2-piperazinyl-pyrimidine derivatives as PI3K and mTOR kinase inhibitors for the treatment of proliferative disorder Butterworth, Sam; Griffen, Edward Jolyon; Pass, Martin WO 2008032060 A1.

Preparation of 4-benzimidazolyl-6-morpholino-2-piperazinyl-pyrimidine derivatives as PI3K and mTOR kinase inhibitors for the treatment of proliferative disorderChloe Atkinson2017-11-07T15:54:42+00:00